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D
iscovery programs for cancer therapy are in-
tently in pursuit of drugs to inhibit the class I
phosphoinositide-3-OH-kinase (PI3K) and tar-
get of rapamycin (TOR) protein kinase (1). PI3K and TOR
activate PKB (also known as Akt) in response to growth
factors (2, 3). PI3K induces PDK1 to phosphorylate the
activation loop of PKB (Thr308). TOR, in TOR complex 2,
phosphorylates Ser473 in the C-terminal hydrophobic
motif of PKB (3). Active PKB in turn switches on growth
and survival pathways (1). TOR complex 1, activated in
response to growth factors and nutrients, also contrib-
utes to cell growth by phosphorylating the translation
regulators S6K and 4E-BP. Genetic abnormalities in can-
cers frequently result in activation of PKB, by loss of
the tumor suppressor PTEN or by activating mutations
of PI3KC. Other class I PI3KCs are also deregulated in
cancer, depending on the malignancy (1). A current goal
is to bring compounds that inhibit speciﬁc PI3KC sub-
types to clinical trials as soon as possible. Structures for
PI3KC(4)andPI3KC(5−7)havegreatlyaideddrugde-
sign for PI3K and have provided insight on the enzy-
matic function and regulation of PI3K. (For abbrevia-
tions and acronyms used, see ref 8. )
Class I PI3Ks are bound and activated by Ras-GTP.
Ras-GTP binding leads to derepression of inter- or in-
tramolecular steric inhibition and targeting of PI3K to
membranes by adapters (9). All class I PI3K enzymes
haveseveraldomainsincommon,includingaRBD(Ras-
binding domain), a C2-domain, a helical domain, and a
catalytic domain. PI3Ks are well-understood in compari-
son to PI3K-related protein kinases such as TOR, due in
part to the availability of structures for PI3K, including a
structure for a Ras-activated form of PI3KC (10).
The PI3K-related kinases (PIKKs), including TOR,
Mec1/ATR, Tel1/ATM, SMG-1, and DNA-PK (see ref 11
for overview) have a catalytic domain related to PI3K but
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ABSTRACT TOR (Target of Rapamycin) is a highly conserved Ser/Thr kinase
and a central controller of cell growth. Using the crystal structure of the related
lipid kinase PI3KC, we built a model of the catalytic region of TOR, from the FAT
domain to near the end of the FATC domain. The model reveals that activating mu-
tations in TOR, identiﬁed in yeast in a genetic selection for Rheb-independence,
correspond to hotspots for oncogenic mutations in PI3KC. The activating muta-
tions are in the catalytic domain (helices k3, k9, k11) and the helical domain
of TOR. Docking studies with small molecule inhibitors (PP242, NVP-BEZ235, and
Ku-0063794) show that drugs currently in development utilize a novel pharma-
cophore space to achieve speciﬁcity. Thus, our model provides insight on the regu-
lation of TOR and may be useful in the design of new anticancer drugs.
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www.acschemicalbiology.org VOL.4 NO.12 • ACS CHEMICAL BIOLOGY 999Figure 1. Structural alignment of TORs and PI3KC. The TORs are human TOR (NP_004949.1), S. cerevisiae TOR1 (P35169.3) (TOR1Sc) and TOR2
(P32600.3) (TOR2Sc), and S. pombe TOR2 (NP_595359.2) (TOR2Sp). The PI3KCs are human PI3KC (CAA82333.1) and pig PI3KC
(NP_999104.1). The structural elements are drawn from 1e8x and color-coded according to a scheme used throughout for TOR domains (8): FAT,
sky blue; FRB, green, CAT, red; FIT (see text for domain deﬁnition), cyan; portion of the FATC, magenta. See Methods for tools used in this
manual alignment.
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tive, checkpoint responses to genotoxic or nutritional
stress activated in cancers. All are important drug tar-
gets, yet there is no structure available for the catalytic
region of any PIKK. TOR signaling is particularly complex,
as TOR is in two structurally and functionally distinct
multiprotein complexes (TORC1 and TORC2) (2). TORC1
in all eukaryotes controls cell growth in response to nu-
trients (2, 3, 12). In metazoans, TORC1 also controls
growth in response to growth factors. The growth factor
signal, including insulin, is transmitted to TORC1 via
PKB-mediated phosphorylation and inhibition of TSC1-
TSC2, a heterodimeric GTPase activating protein (GAP)
for Rheb. Upon inhibition of TSC1-TSC2, active Rheb
binds and activates TORC1. The mechanism by which
TORC1 integrates nutrient and growth factor signals is
not clear but appears to occur at the level of TORC1.
Growth factors also activate TORC2, but by an unknown
mechanism independent of Rheb.
The PIKKs share a helical domain (FAT) of 500 resi-
dues, a catalytic domain with motifs related to PI3K, and
a short but highly conserved C-terminal FATC domain.
The helical and FATC domains ﬂank the catalytic do-
main. A portion of the helical domain in TOR is known
as the FKB12-rapamycin binding (FRB) domain. Rapa-
mycin inhibits TORC1 function by binding this domain.
Rapamycin analogues are now approved anticancer
drugs. However, variability in growth inhibition limits
the potential of rapamycin analogues as single agents.
Rapamycinanaloguesassingleagentsmaynotbeeffec-
tive anticancer agents because they do not inhibit
TORC2 and because they inactivate a TORC1-mediated
negative feedback loop, thereby increasing PKB and
MAP kinase activity (2, 3, 13).
Recently, both academic and industry scientists have
reported isolation of TOR inhibitors identiﬁed by activ-
ity screens (14−17). Some PI3K-inhibitors (PI-103 (14),
NVP-BEZ235 (16)) selectively inhibit both PI3KC and
TOR without appreciably inhibiting other protein ki-
nases, including other PIKKs. Torin1 (17), PP242 (18),
andKu-0063794(15)aremorespeciﬁcforTOR,whether
TOR is in TORC1 or TORC2. Drug discovery urgently
needs structures for PIKKs, and hopefully these are
soon forthcoming. Attempts to model TOR to related
PI3Ks, either for insights in drug design or for insights
on regulation and function of TOR, have been hampered
by the fact that the regions of obvious sequence similar-
ity between TOR and PI3Ks are too limited for auto-
mated alignment programs used by computational bi-
ologists. A homology-based model of part of the ATP-
binding site of TOR was recently described (see
Discussion).
We were able to build a model of the catalytic region
ofTORbasedontheknowncrystalstructureofPI3K,af-
ter manual alignment of amino acid sequences of the
two kinases. We identiﬁed new motifs, conserved be-
tween TORs and PI3Ks and also conserved between TOR
andotherPI3K-relatedkinases.Ofparticularinterest,ac-
tivating mutations in TOR structurally correspond to acti-
vating mutations in PI3KC, suggesting a key regulatory
role for the RQD (k3) and k9 helices in TOR. Further-
more, our model may be valuable for drug discovery, as
shown by docking PP242, NVP-BEZ235, and Ku-
0063794 into the active site and deﬁnition of putative
binding modes in TOR.
RESULTS
Criteria for Alignment of TOR and PI3KC Sequences.
To construct a model of the structure of the TOR cata-
lyticregion,wealignedthesequencesofTORandPI3KC.
To determine the catalytic region of TOR, we ﬁrst com-
pared 100 TOR sequences from various organisms, by
using ClustalW. We found blocks of conservation sug-
gesting that the catalytic region of TOR begins near resi-
due 1800 near the deﬁned FAT domain. We then manu-
ally aligned amino acid sequences of several TORs and
PI3KCs, beginning near the FAT and the helical domains,
respectively, using several criteria and tools (see Meth-
TABLE 1. Residues near to ATP in human
TOR
Residue In structure Conservationa
Ser2165 k3k4 100%, as Ser/Thr
Pro2169 k4 100%
Lys2187 k5 100%
Tyr2225 k6 100%, as Tyr/Phe
Ile2237 k7 100%, as b
Val2240 k7k8 98%, as Val
Met2345 k9 81%c
Leu2354 k10 100% as b
Ile2356 k10 96%d
aPercentages from one hundred and ten sequences. b
(Leu/Val/Ile/Met). cLeu 19% . dVal 4%.
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ment of ﬁve TORs and two PI3KCs (Figure 1). We looked
for conserved residues in TORs taken from all across
the animal and plant kingdoms (manuscript in prepara-
tion). We collected, validated, and trimmed 100 TORs
soastobeginnearresidue1860.Smallersetsofdiverse
sequences for PI3Ks (classes I, II, and III) were also col-
lected and trimmed to begin at the helical domain. We
evaluated many factors as we made the alignment, in-
cluding conservations within homologous proteins, pre-
dictionsofpropensityofTORresiduesforstructureindif-
ferent views in MacVector, as well as views of the PI3K
structures at the NCBI with Cn3D. Hereafter, we use the
deﬁned structural elements from PI3KC (6) throughout
for discussion. Furthermore, residue numbers given be-
low for TOR refer to the position of the residues in hu-
man TOR, unless otherwise indicated.
Alignment of the Catalytic Loop of TOR. TORs have
short regions of near identity that are the main features
deﬁning the PI3K-related kinase group. The segment
21802381 of human TOR is clearly similar to PI3KC.
ThemotifK2187GHEDLRQDisintheN-terminallobeofthe
catalytic domain in TOR. In PI3KC, Lys2187 corre-
sponds to the wortmannin-reactive lysine within the
N-terminal lobe (in k5) and the conserved RQD (under-
lined) is in k3( 6). There are other key motifs in resi-
dues 22602317 of TOR that contain strong identities
to PI3KC. Ser2323 of TOR is in the center of a predicted
helix equivalent to k6 of PI3KC. This predicted helix is
followed by the catalytic loop GLGDRHPS. The triplet
DRH is always followed by a proline in TORs and de-
ﬁnes a unique feature. Proline is never found at this po-
sition in any non-TOR PI3K-related kinase or in any
PI3KCs or PI4K. The aspartate of the DRH motif (D2338
in TOR) is thought to be the catalytic base for the phos-
phate transfer reaction in protein kinases.
Alignment of the Activation Loop of TOR. The activa-
tion loop of TOR begins with a DFG motif. The aspartate
of the DFG motif (D2357) positions a key Mg2 ion nec-
essaryforcatalysis.TheendoftheactivationloopinTOR
is less easily recognized. The end of the activation loop
is usually deﬁned by an APE motif in protein kinases.
The activation loop of TOR has a conserved PE motif
(residues 2372 and 2373). PE is conserved in this posi-
tion in all of the PIKKs, but is absent in the activation
loop of PI3Ks. The activation loop of PIKKs, as deﬁned
by the DFG and PE motifs, is considerably shorter than
Figure 2. TOR compared to PI3KC. a) A portion of the FRB domain (8)
corresponds to the helical domain (FAT (8) domain), and a portion is the
helix k1 of the catalytic domain of PI3KC. Two inserts cannot be
modeled to PI3KC. One is early in the FIT (8) domain (deﬁned as resi-
dues 24272516) between the catalytic and FATC domains. The other
is in the catalytic domain. Coloring of PI3KC (1e8x): blue, helical do-
main; yellow, catalytic domain. The C-terminal part of the FIT domain
forms the C-terminal helices in PI3KC (k10-k12). A portion of the
FATC (8) has no template in 1e8x but either overlaps or is appended to
k12. b). A rotation shows the key structural roles of the RQD helix
(k3) and k9. The k9 ends the conserved catalytic domain of TOR.
Insertion of the undeﬁned portion of FIT domain is at the two stubs
(asterisks).
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versus 2335 residues).
The activation loop of TOR ends with k7. Part of
k7 is similar in sequence to the F-helix that follows
the activation loop in the C-subunit of cyclic AMP-
dependent protein kinase. A consensus for a sequence
at the end of the activation loop in TOR, spanning the PE
as well as a putative P1 loop, can be given as PE
(K/R) (V/I) PFRL. This motif is conserved in all TORs.
AlignmentofATPBindingResiduesinTOR.ATPbinds
to PI3KCusing polar contacts made to phosphates and
hydrophobic contacts made to adenine (6). Building
the ATP binding site requires short -strands (k110
in PI3KC) which present conserved residues that con-
tact ATP. This is unlike the ATP binding mode of typical
protein kinases (19), which use the conserved, ATP-
binding motif GxGxxGxV (x, any amino acid), not found
in PI3KCs and PI3K-related kinases. Furthermore, the
novel mode of ATP binding by PI3KCs requires a key
serine (Ser806 in PI3KC) that interacts with the
-phosphate of ATP (6). We expected this mode of ATP
bindinginPI3KCtobeconservedinTOR,andwesought
to identify -strands conserved in all TORs that corre-
spondtok110inPI3KC.Automatedalignmentshave
failed to align the region N-terminal to the equivalent of
Ser806 critical for ATP binding. Predicted catalytic do-
mains for TOR, such as CD05169 at NCBI, are unlikely to
bind ATP because they commence too far toward the
C-terminus,atbestatIle2153inthemiddleoftheequiva-
lent of k2 in PI3KC. One factor contributing to this con-
fusion may be that all of the PI3KCs (classes IIII) have
a PxxP motif between k1 and k2, exactly 16 residues
N-terminal to the serine equivalent to Ser806 in PI3KC,
and this motif is not present in TOR or any other PI3K-
related kinases. Thus, a key to making a structural align-
ment of TOR to PI3KCfor homology modeling was to dis-
cover the conserved residues presented by k110 in
TOR. The residues we identiﬁed are summarized, with
their conservation in the 100 TOR sequences, in
Table1. Identiﬁcationoftheseresidueslocatesk310
in TOR. We then identiﬁed the probable boundaries of
the -strands based on conservations and propensity to
form -strands using tools in MacVector during manual
alignment. We then adjusted gaps between the pre-
dicted k15 in this region (Figure 1).
Ser2165 in TOR corresponds to Ser806 in PI3KC,
presented in the loop between k3 and k4 to interact
with the -phosphate of ATP. This serine is characteris-
tic for a mode of ATP binding predicted to be shared by
TOR and is 100% conserved in TORs. Ser2165 is aligned
in automated alignments of PI3KCs to TORs. Further-
more, the k14 strands were difﬁcult to identify in
TORs, but a key proline helped deﬁne a boundary for
k1 in TORs. This proline, Pro2141, is conserved in
100% of TORs. Pro780 in PI3KC aligns with Pro2141
in TOR. Pro780 appears to be conserved in all PI3KC’s
from different species.
We identiﬁed other residues in TOR that should be
near ATP, also summarized with their conservation in
Table 1 and ampliﬁed upon as follows. Lys2187 in k5
has to be in the ATP pocket. This lysine (Lys833 in
PI3KC) should interact with the -phosphate of ATP.
Pro2170 is conserved in all PIKKs and is equivalent to
Pro810 in PI3KC. Pro810 packs against the hydrocar-
bons of the side chain of Lys833, in a position to stabi-
lize the interactions of the -amine of Lys833 for cataly-
sis. Tyr2225 in k6 has to be positioned in a speciﬁc
conformation if TOR is to bind ATP. Tyr2225 corresponds
to Tyr867 in PI3KC. Tyr867 is positioned with the phe-
nolicringnearlyperpendiculartotheadenineringofATP
and with adenine C6-NH2 4 Å away. This aromatic hy-
drophobicresidueisconservedastyrosineorphenylala-
nine in all PI3Ks and PIKKs. Ile2237 is in motif GLIGW
in k7. Gly2235 begins a similar motif found in the cata-
lytic domain of every PI3K and PIKK. The two residues af-
ter Gly2235 are always hydrophobic. Ile2237 is Ile879
of P3KC. Ile2237 aligns with the so-called gatekeeper
residues in other kinases. The hinge region (residues
22382246) adjacent to the gatekeeper contains
Val2240, located between k7 and k8, that should
make interactions with the adenine ring of ATP. This
Val882 in PI3KC lies at the bottom of the ATP pocket.
The short loop between k7 and k8 is the deepest wall
of the ATP binding pocket (6), and Val882 provides two
hydrophobic contacts with adenine. Met2345 is in k9,
a -strand in the predicted larger lobe of the kinase.
Leu2354 precedes the DFG motif, replacing Phe961 in
PI3KC. The aromatic ring of Phe961 is at the bottom of
the ATP pocket. This phenylalanine is found in 100%
of PI3K sequences (classes I, II, III), and precedes the
DFG motif of the activation loop. In all TORs, as well as
in PI3K-related kinases in general, this residue is never
aromaticandisalwaysanaliphatichydrophobicresidue
(Leu/Val/Ile/Met).
Identiﬁcation of a WLK Motif in TOR. We identiﬁed
an insertion that we place between k4 and k5i n
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2288) was helped by discovery of a WLK motif that iden-
tiﬁes k5. The WLK sequence is in 	90% of TORs. The
tryptophan (Trp2304) is particularly well conserved,
found in 100% of the approximately 100 TOR se-
quences examined. A similar motif is present in almost
all PI3KCs (classes I and II). Recognition of the WLK mo-
tif as marking k5 facilitated subsequent alignments.
There is a shorter gap in TORs in the surface loop that
lies between k7 and k8 in PI3KC. This is then fol-
lowed by longer helices k8 and k9 that are similar to
helices in PI3KC.
End of the Catalytic Domain. The end of conserva-
tion in the catalytic domain in TORs occurs abruptly,
marked by an invariant FxxDPL motif (F2421xxDPL in hu-
man TOR). The next residue is also strongly conserved
(97%) as isoleucine or leucine. We also found a nearly
invariant arginine in TORs and other PI3K-related ki-
nasesnearthismotif,Arg2408inhumanTOR.Thisisno-
table because a conserved arginine is very near the
end of the catalytic domain of Ser/Thr kinases. The con-
served arginine (Arg280 in PKA C-subunit) deﬁnes sub-
domain (XI) in the protein kinases. Arg1021 in human
PI3KCisconservedinallclassIPI3KCsthatwehaveex-
amined, and aligns with Arg2408 in human TOR. How-
ever, Arg1021 in porcine PI3KCis not playing the same
structural role as Arg280. Arg280 in PKA makes a salt
bridge to Glu208 in the APE motif at the end of the acti-
vation loop (19).
Alignment of Helical Domains. We placed predicted
helices from the FAT domain and the deﬁned helices
from the FRB domain upon the deﬁned helices in
PI3KC. This region lacks sufﬁcient similarity to be
aligned by means other than superimposition of poten-
tially corresponding helices, using tools in MacVector to
view potential for helicity according to several scoring
systems. The alignment of predicted helices can be im-
proved by introduction of gaps, but we made the align-
ment that places predicted helices near deﬁned helices
in PI3KC assuming there were no gaps. The entire FRB
domain (residues 20152114) is highly similar in the
approximately 100 TORs examined. The FRB domain
containsafewresiduesthatareinvariantinalltheTORs,
including Glu2015, Leu2016, Arg2017, Glu2025, and
Trp2027 in the sequence ELIRVAILWHE. This key motif
falls near h4 in PI3KC.
Insertion of the FIT domain of TOR. We name the por-
tionoftheC-terminusofTORfromFxxDPLtotheFATCdo-
Figure 3. Residues binding ATP in TOR. a) Orientation of adenine N-6
to Tyr2225 in TOR. Asp2357 is near the - and -phosphates of ATP.
b) Lys2187 is near the -phosphate of ATP.
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TOR). FIT is a useful short acronym and a phonetic con-
trast to the FAT and FATC domains. The FIT domain
showsmoredivergenceinour100TORsthanthecata-
lytic domain, but is highly conserved within speciﬁc
taxonomic subgroups.
The FIT domain contains an insertion relative to
PI3KC. We suggest that the insertion is at the position
corresponding to the very short surface loop between
k9 and k10 of PI3KC. This loop opens to a vacant
space in the PI3KC structure above the active site in
PI3KC, placing Ser2481 near the active site of TOR. In
this context, it is important to note that there is consid-
erable interest in the FIT domain as a regulatory domain
because of three ﬁndings: (i) Ser2448 is phosphory-
latedbyS6K1(20),(ii)the
RDmutantdeletingSer2448
is more active as a kinase (21), and (iii) TOR autophos-
phorylates Ser2481 when TOR is present in TORC2 (22,
23).
Alignment of the FATC Domain. A helix is predicted
to start in human TOR after Pro2522. The helix deter-
mined in the NMR structure (RCSB, PDB 1w1n) of the re-
folded FATC of S. cerevisiae TOR1 begins at Glu2444 fol-
lowing Pro2443 (equivalent to Pro2522 in human TOR)
(24). Pro2522 in human TOR is conserved in all TORs.
The next residue, Thr2523 in human TOR and Glu2444
in S. cerevisiae TOR1, is not conserved in the 100
TORs. Strikingly, the second residue, Gln2524 in hu-
man and Gln2445 in S. cerevisiae, is conserved in the
100 TORs. Other invariant residues (numbered by hu-
man) are Leu2528, Ala2532, Gly2544, and Trp2545. We
chose an alignment that places the deﬁned helix near,
not upon, k12 so as to minimize the size of the gap in
PI3KC and to align predicted helices near the end of
the FIT domain with k10 and k12.
Making a TOR Structure. We used computer rou-
tines provided in the SWISS-MODEL (8.05) server (25)
to build a model for the catalytic region of TOR based on
the above manual alignment of TOR and PI3KC
(Figure 1). The template was PI3KC (RCSB, PDB 1e8x).
This template is a structure for an inactive form of
PI3KC with bound ATP (6). The modeled catalytic re-
gion of human TOR is residues 19062526.
The backbone structures of human TOR and PI3KC
are compared in Figure 2. The TOR model shows that
the FRB domain (residues 20152114) corresponds to
aportionofboththehelicaldomainandthecatalyticdo-
main of PI3KC. The FRB domain covers helices hA4,
hB4, hA5, and hB5 of the helical domain and helix k1
of the catalytic domain of PI3KC.
ThereisaninsertinTORinthecatalyticdomain(chain
colored red) in the loop between k4 and k5 (Figure 2,
panel a). This loop is ten residues in PI3KC, and is ex-
panded to 47 residues in TOR. The ﬁrst residues (RE-
KKK) of this loop in TOR form a cluster of charged resi-
dues that imposes a requirement for surface exposure.
Figure 4. Pharmacophore space in TOR. a) The -phosphate of ATP
(gray) is exposed. b) A pharmacophore space lies below the active site.
This space is also in the PI3KC structure (see Supplementary Figure
S1). See ref 8 for deﬁnitions of domain acronyms FAT, FRB, CAT, FIT,
and FATC.
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panded loop between k4 and k5 may remain as a
loop or form a surface helixloophelix.
The FIT domain (chain colored in cyan) is mostly un-
deﬁned in the TOR model (Figure 2, panel a). Sequences
toward the end of the FIT domain form helices k10
and k11. A portion (chain colored in magenta) of the
FATC domain corresponds to k12. Residues in the ter-
minating helix k12 (residues 10811090) and in the
remainder of the C terminus (residues 10911102) of
PI3KCare closer to ATP than generally appreciated. The
side chain NH2 of Gln1083 in k12 of PI3KC is 10.6 Å
from oxygen of the -phosphate. Trp1086 in k12 is
within 12 Å of the -phosphate. These distances are too
large for direct contacts. However, no other residues lie
between Gln1083 and Trp1086 and the -phosphate in
the structure of ATP-bound PI3KC, suggesting that
these residues either line a substrate pocket or steri-
cally inhibit access of substrate. The portion of the FATC
domain that was not modeled (residues 25272549)
is short and, whatever its fold, is constrained to also be
near the active site. Thus portions of the FATC domain
(RCSB, PDB 1w1n), including the helix and unique Cys-
containing structure, which cannot be modeled, are
likely to be close to the active site in a determined
structure.
In Figure 2b, the undeﬁned portions of TOR are
trimmed to visible stubs, and the superimposed back-
bones for the TOR model and PI3KC are rotated so as
to look along the axis of helix k3. The stubs (cyan,
asterisks) show where the undeﬁned portion of the FIT
domain is inserted in TOR. The FIT domain emerges
above the active site, where there is space for a subdo-
main on the surface of the C-terminal lobe of the cata-
lytic domain before its C-terminal portion merges into
k10 and k11. The ﬁrst and last residues of the FIT do-
mainshown(cyan)areAsn2428andVal2475.Ser2481,
which is autophosphorylated by TOR in TORC2 (22),
must be near the active site of TOR. Insertion of the FIT
domain at the surface loop between helices k10 and
k11 of PI3KC may place Ser2481 near the active site
where it can be phosphorylated.
The k3 and k9 helices were built and superim-
posed upon the corresponding helices from PI3KC.
TABLE 2. Mutations in yeast TORs
Gene Mutation Domain Phenotypea Human TOR ref
TOR1_Sc I1954V,T FRB 1 R to caffeine I2017 26
TOR1_Sc A1957V FRB 1 R to caffeine A2020 26
TOR1_Sc W2176R,C Kinase 1 R to caffeine W2239 26
TOR2_Sc I1957T FRB 1 R to rapamycin I2017 29
TOR2_Sc A1960V FRB 1 R to rapamycin A2020 29
TOR2_Spb Y1986C Kinase 2 Glycogen F2182 30
TOR2_Spb E2221K Kinase 2 D on Rheb E2419 30
TOR2_Sp L2048S Kinase 1 G1 arrest L2246 32
TOR2_Sc G2129Rc Kinase 2 Endocytosis G2188 33
Chimeric V2198A Kinase 1 Rt olst8ts V2198 29
mTOR L2216H L2216
(SL1)d L2260P L2260
Chimeric A2290V Kinase 1 Rt olst8ts A2290 29
mTOR K2440R FIT K2440
(SL2)d
Chimeric L2302Q Kinase 1 Rt olst8ts L2302 29
mTOR
(SL3)d
aR, resistance; D, dependence. bS. pombe Tor2 corresponds to S. cerevisiae Tor1. cG2128R (typo) in the reference. dChi-
meric ScTOR2 (11689) and rat TOR (17212549), multiple mutations were in two of three isolated mutants.
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lytic domain for TOR. The k3 and k9 helices run
through the core of PI3CK and above the active site.
The helix k3 (the RQD motif-containing helix) positions
residues in the loop preceding RQD near the active
site. In the view of Figure 2, panel b, k3 runs into the
page. After building the remaining -sheet elements re-
quired for the ATP pocket, the polypeptide chain returns
to the opposite side of the molecule to pass back
through the core as helix k9. The returning helix k9
runs nearly parallel to k3 and above it, but with an op-
posite directional vector. Thus, helix k9, which comes
inlinearsequencefromneartheC-terminus,isplacedin
position to stabilize k3. Correct placement of k9
above k3 in TOR required discovery of the gaps and in-
serts as shown in the structural alignment (Figure 1).
ATP Binding to TOR. Residues in TOR equivalent to
residues for ATP binding in PI3KC (Table 1) are shown
in relation to ATP and two Lu3 ions from the 1e8x tem-
plate (Figure 3). The plane of the adenine ring of ATP in
TOR is nearly perpendicular to that of Tyr2225, with the
C6-NH2oftheadenineringpointingtowardthearomatic
ring of Tyr2225. The -NH2 of Lys2187 is 3.32 and 3.49
Å in distance from an oxygen of the -phosphate of
ATP (Figure 3, panel b). Ser2165 is in proper position
with its side chain -OH pointing toward oxygens of the
-phosphateofATP(notshown).ThismodeofATPbind-
ing supports the structure built for TOR on the PI3KC
template.
Surface views of ATP in TOR reveal an important ﬁnd-
ing (Figure 4). The domains of TOR are again colored as
for the backbone structure of TOR. One sees an ex-
pected pocket in the catalytic domain (colored in red)
that lies above and beside the -phosphate of ATP (col-
ored in gray) (Figure 4, panel a). The missing portion of
the FIT domain emerges somewhere above this pocket
in our model. The surprise is that, in the TOR model, por-
tions of the ribose ring are not buried but are exposed
in a groove that extends along the bottom of the sub-
strate pocket (Figure 4, panel b). Portions of the adenine
ring of ATP are also visible (not shown). In structures of
PKA, adenine and the ribose are completely buried, in
the most closed structure with ATP and inhibitor peptide
(1ATP) and in the structure for a transition state mimic
(19). The observation we make here for TOR is also seen
with a similar projection for PI3KC. ATP is partially ex-
posed in a similar groove that is below the active site of
PI3KC (Supplementary Figure S1).
Yeast TOR Protein Mutations. Characterized muta-
tions in yeast TOR proteins (Table 2) can be used to vali-
date our model. Caffeine is a TORC1 inhibitor, and a ge-
netic selection for caffeine resistance in S. cerevisiae
identiﬁed mutations in TOR1 (26). Caffeine, which mim-
ics adenine, can bind a subset of sites for adenine nu-
cleotides, including the site in the PI3K-related kinase
ATM (27), but appears to be more speciﬁc for TORs in
TORC1invivoincomparisontootherPIKKs(28).Thecaf-
feine resistance mutations in TOR1 decrease afﬁnity for
caffeine or confer increased TORC1 kinase activity. The
Figure 5. Location of mutations in model of S. cerevisiae TOR1. a) Muta-
tion of Trp2176 in the adenine pocket increases resistance to caf-
feine. Mutations of Ile1954 and Ala1957 in the FRB domain activate
TOR1. View is from the back. b) Trp2176 is a TOR-speciﬁc difference in
the adenine pocket. Enlarge to see side chains (orange) of mutated
residues.
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feine.Trp2176isconservedinallTORsandisintheATP-
binding pocket in our model (Figure 5). Trp2176 aligns
with Ile881 in PI3KC and is in the short loop between
k7 and k8. The view of Trp2176 (Figure 5, panel a) is
from the back of the molecule, with the active site go-
ing into the page. The indole ring of Trp2176 is posi-
tioned close to the adenine ring of ATP (Figure 5,
panelb).Theconservedvalinesfollowingthesetworesi-
dues are superimposed. The presence of tryptophan at
this position in all TORs versus an aliphatic residue as in
all PI3KCs is a signiﬁcant difference in the adenine
pockets.
Mutations of Ile1954 and Ala1957 in S. cerevisiae
TOR1 increased TORC1 kinase activity, conferring caf-
feine resistance without affecting caffeine binding at the
ATP site (26). The kinase activating mutations in TOR1
(I1954V, A1957V) are in the helical domain portion of
the FRB domain in helix hA4 outside the catalytic do-
main (Figure 1). Similar activating mutations (I1957T,
A1960V) in S. cerevisiae TOR2 confer mild resistance to
the TORC1 inhibitor rapamycin (29), again suggesting
that they indeed activate the kinase. Helix hA4 is be-
tween hB3 and hB4 in the helical domain of PI3KC.
In the ﬁssion yeast S. pombe, a selection for mutants
that grow in the absence of the TOR activator Rhb1
(Rheb) produced 22 mutants with activating mutations
in TOR2 (30). S. Pombe TOR2 (like S. cerevisae TOR1) is
found predominantly in TORC1, and the biology of the
TORs in the two yeasts is somewhat different as well
(31). Interestingly, these activating TOR2 mutations also
clustered in the helical domain and the kinase domain
(Figure 6, panel A). Activating mutation Y1986C in S.
pombe TOR2 is in k5 just before the RQD helix k3;
V2000L and F2004C are in the RQD helix (k3); E2221K
and A2218 are both in k9. I2229T is just after the con-
served DPL motif that ends k9. L2289F and N2294I
are in k11.
The L2048S mutation in S. pombe TOR2 confers a
cell cycle arrest and rapamycin hypersensitivity (32),
suggesting that it is a loss-of-function mutation. This is
consistent with the structural position of Leu2048
(Figure 6, panel B). Leu2048 is just after k8, following
a threonine residue that is conserved in all TORs and
PI3Ks. Importantly, Leu2048 is buried near k9 (the
C-terminal anchor of the catalytic loop) and k10 (N-
terminal anchor of DFG motif). The equivalent structur-
ally important residue in PI3KC is Ile888.
Activating mutations in mammalian TOR were iso-
lated in a chimeric TOR, S. cerevisiae TOR2 (11689)
fused to rat TOR (17212549), by selecting in yeast the
Figure 6. Sites of activating mutations in S. pombe TOR2. A) Front and
B) rear of molecule. Included in view is the site (L2048) of an inactivat-
ing mutation of S. pombe TOR2. Double arrow shows the key helices,
k3 (the RQD) and k9 in PI3K-related kinases. Enlarge to see side
chains (orange) of mutated residues.
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both TORC1 and TORC2) (29). Of the mutant strains
that were generated by this selection, mutant SL1 had
three mutations in the chimeric TOR, V2198A, L2216H,
and L2260P. V2198A is in the RQD helix k3 and, we
suspect, causally related to the increased TOR activity,
whereas L2216H and L2260P are in loops. Furthermore,
L2260 is already a proline in S. cerevisiae TOR1 and
TOR2. Mutant SL2 had two mutations, A2290V in the
k4k5 loop and K2440R in the FIT domain. Mutant
SL3 had a single mutation, L2302Q, in k5. SL1 had the
most active TOR of the three mutant strains, supporting
the importance of the RQD helix.
Finally, the S. cerevisiae TOR2 mutation G2129R
causes caffeine sensitivity and reduces TOR2 activity
(33). Gly2129 is adjacent to Lys2128, the essential,
wortmannin-sensitive lysine conserved in TOR (Figure 3,
panel b). This suggests that G2129R might inhibit ki-
nase activity by positioning this lysine to interfere with
ATP binding.
Structure-Based Design of TOR Inhibitors. (See
Supplementary Figure S2 for chemical structures of all
small molecules.) Apsel et al. (5) reported two pyrazol-
opyrimidine compounds that inhibit PI3KC. Compound
S1 is a precursor for PP242, reported as a selective in-
hibitor for TOR in both TORC1 and TORC2 (18). Com-
pound S2, related to compound S1, was crystallized in
human PI3KC (RCSB, PDB 3ene). Because the pyrazol-
opyrimidine rings of S1, S2, and PP242 are planar and
quite similar, we asked if PP242 with its pyrazolopyrim-
idine ring can ﬁt into PI3KC. We ﬁrst placed S2 bound
to human PI3KC (3ene) into the reference coordinates
of our template porcine PI3KC (1e8x). The pyrazolopy-
rimidine of S2 with its attached methyl group ﬁts neatly
intoPI3KC,withthesecondnaphthaleneringpositioned
inside the pocket for adenine (Figure 7, panel A). The
pyrazolopyrimidine of PP242 with its larger isopropyl
moiety has clashes in PI3KC(Figure 7, panel B). In con-
trast, when we placed PP242 in TOR and superim-
posed the core pyrazolopyrimidine rings (34), TOR had
sufﬁcient space to accommodate the isopropyl moiety
of the pyrazolopyrimidine ring of PP242 (Figure 7, panel
C).
The dihedral angle for torsion between the two rings
in S2 bound to PI3KC in 3ene was 45.4°, but in S2
the second ring is simple naphthalene. PP242 has a
more polar 5-hydroxy indole moiety instead of naphtha-
lene as its second ring (Supplementary Figure S2). The
potential for polar contacts for 5-hydroxy indole of
PP242 in the adenine pocket was estimated in Mac-
Pymol by rotations about this bond maintaining the
pyrazolopyrimidine portion ﬁxed. PP242 with dihedral
angles of 100° to 40° had potential for 3 polar con-
tacts, with one in the adenine pocket. A dihedral angle
of 130° is rotated 180 degrees and had potentially four
polar contacts, with two in the adenine pocket.
We used AutoDock4 (35, 36) to predict a binding
mode of PP242 to TOR (Figure 8, panel A), using com-
pound S2 (Supplementary Figure S2) crystallized in hu-
man PI3KC (RCSB, PDB 3ene) to deﬁne a starting posi-
tion. All of the residues shown have at least one atom
within4Åo fPP242. The 4-amino nitrogen of pyrazol-
opyrimidine makes a hydrogen bond to the backbone
oxygen of Gly2238. Gly2238 is adjacent to the gate-
keeper, near the hinge region. The 5-hydroxy of the in-
dole of PP242 makes a polar contact with the -NH2 of
Lys2187 of TOR. Interestingly, the m-phenol of com-
pound S1 (Supplementary Figure S2) interacts with the
-NH2ofLys833ofhumanPI3KC(5).Thishelpsexplain
PP242 inhibition. Lys2187 is required for catalysis. The
4-amine of the pyrazolopyrimidine is nearly positioned
to make a -cation bond with the aromatic ring of
Tyr2225.
We also predicted a binding mode for NVP-BEZ235
to TOR using AutoDock4 (Figure 8, panel B). The coordi-
nates for staurosporine in PI3KC (RCSB, PDB 1e8z)
were used to generate a starting position for NVP-
BEZ235 in TOR. Maira et al. (16) proposed a mode of
binding of NVP-BEZ235 to PI3KC based on this 1e8z
Figure 7. Manual docking of PP242 in TOR. A) S2 with its methyl group
ﬁt in PI3KC structure (3ene). B) PP242 hindered by wider isopropyl
group in PI3KC. C) PP242 can ﬁt into the TOR model. The pyrazolopy-
rimidine rings of PP242 and S2 were superimposed to position PP242
(see text). The images were generated with MacPyMol (DeLano Scien-
tiﬁc).
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have at least one atom within4Åo fligand. Ligands: carbon atoms, gray; nitrogen, blue; oxygen, red. Dashed lines, bonds. A) PP242. Leu2185 is
omitted. B) NVP-BEZ235. C) Ku-0063794. Pro2169 and Lys2187 are omitted.
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the TOR model with AutoDock4 are somewhat different.
The quinoline ring of NVP-BEZ235 is perpendicular to
the aromatic ring of Tyr2225, taking a similar position
as the adenine ring of ATP takes with the aromatic ring
of the equivalent tyrosine in PI3KC. The nitrile nitrogen
makes polar contacts in the catalytic loop with the
Ser2342 side chain OH as well as with the Asn2343
backbone oxygen.
Ku-0063794 (Supplementary Figure S2) came from a
chemical series identiﬁed in a drug discovery program
forPIKK(ATM,ATR,DNA-activatedPK)inhibitors,buthad
no prior report until a report of its speciﬁcity for TOR
(15). Ku-0063794 is speciﬁc to TOR in TORC1 or TORC2
and does not inhibit PI3K (15). Ku-0063794 is an espe-
cially interesting small molecule. It has a central 1,3,8-
triaza-napthalene core (also known chemically as
pyrido[2,3-d]pyrimidine), and three radiating append-
ages, 4-[morpholine], 2-[dimethymorpholine], and 7-[3-
hyroxymyethyl, 4-methoxy phenyl]. These appendages
give the molecule an overall Y-shaped appearance.
We used ATP in PI3KC(1e8x) to approximate a start-
ing position for Ku-0063794 for docking experiments
with PI3KC and TOR. Ku-0063794 did not have any
docked conformations to PI3KC, consistent with the
speciﬁcity reported for TOR versus PI3KC. In the best of
the docked conformations (Figure 8, panel C), Ku-
0063794 binds with one arm of the Y in the adenine
pocket and another along the hinge toward the posi-
tion taken by the -phosphate of ATP. The morpholine
ring oxygen was near Val2240. This potential interaction
is of interest because the PI3K inhibitor LY22490 binds
to PI3KC in a mode wherein oxygen of the morpholine
ringishydrogenbondedtobackbonenitrogenofVal882
of PI3KC. Val2240 of TOR is the equivalent residue.
The OH of the 3-hydroxymethyl is hydrogen bonded
to the side chain of Gln2161. The OH of the 4-methoxy
is hydrogen bonded to the backbone nitrogen of
Thr2164. Conformations rotated 180 around the bond
connecting the base of the Y to the core were 1.5 kCal
less favored but still plausible, and placed the dimethyl-
morpholine ring in the adenine pocket near Ty2225,
Ile2356, Ile2237, and Leu23185. In this pose, Ku-
0063794 retains the H-bonding interactions with
Gln2161 and Thr2164.
A shortcoming of the docking studies is that the pre-
dicted negative energies of binding do not account for
the reported nanomolar Ki for TOR inhibition in cells by
PP242 (18), NVP-BEZ235 (16), and Ku-0063794 (15).
The highest scoring conformations with AutoDock4 gave
us 7.08 kCal/mol, 8.82 kCal/mol, and 8.44 kCal/
mol for PP242, NVP-BEZ235, and Ku-0063794, respec-
tively. This may be due to an imperfect model or to
AutoDock4 scoring. Both, especially the former possibil-
ity, are likely. Work to reﬁne the model is ongoing.
AutoDock4 is not always accurate for small molecule in-
hibitors in pockets where hydrophobic interactions and
hydrogen bonds are very important (37).
Achieving TOR Speciﬁcity by Use of a Novel
Pharmacophore Space. A novel space for pharmacoph-
ores exists in a channel that runs from the bottom sur-
face of TOR inward toward the ATP and substrate pock-
ets. PI3KC has, and TOR is predicted to have, a relatively
ﬂat bottom (Figure 4 and Supplementary Figure S1).
The longitudinal axis of ATP is roughly perpendicular to
the axis of this channel. A pocket that lies immediately
adjacent to the -phosphate may serve to position sub-
strate OH for phosphate transfer.
The predicted binding modes of PP242, NVP-BEZ235,
and Ku-0063794 are compared to ATP in Figure 9. All
three compounds have a ring roughly perpendicular to
Figure 9. Superposition of the predicted binding modes of PP242, NVP-
BEZ235, and Ku-0063794. PP242, carbons, magenta; NVP-BEZ235,
carbons, gray; Ku-0063794, carbons, yellow.
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and PP242 is TOR-selective, while BEZ-235 inhibits both
TOR and PI3KC. Their speciﬁcity may be rationalized by
the way these lead compounds make use of the novel
pharmacophore space in TOR. The isopropyl group of
PP242 is too wide to be accommodated at a critical po-
sition in the channel in PI3KC (Figure 7), yet overall
PP242 is the smallest compound and occupies the
smallest portion of the pharmacophore space. NVP-
BEZ235 and Ku-0063794 make different use of the
pharmacophore space. A portion of NVP-BEZ235
projects into the space, but its 4=-(2-cyano-2-propyl)
phenyl group is hooked back by its geometry so that
the nitrile is placed near residues in the catalytic loop.
Ku-0063794issufﬁcientlylongintheportionwecallthe
base of the Y to bring the base’s polar groups into con-
tact with polar surface residues that line the opening of
thechanneluponthebottomsurface.Ku-0063794must
be too large for the smaller space in PI3KC, as Ku-
0063794 had no docked conformations in PI3KC. The
dual speciﬁcity of BEZ235 for TOR and PI3KC may be
due to its unusual geometry that keeps major parts of
it in the conserved ATP binding pockets of the two ki-
nases. The differences in degree of occupancy of the
novel pharmacophore space in TOR can be appreciated
by comparing surface views of docked PP242, NVP-
BEZ235, and Ku-0063794 (Figure 10).
DISCUSSION
We discovered that activating mutations in TOR identi-
ﬁedingeneticselectionsareinthehelical,catalytic,and
FIT domains in our structure for TOR. Oncogenic muta-
tions in PI3KC are also concentrated in the helical and
catalytic domains and in the C-terminus in helix k11
that corresponds to a portion of the FIT domain. In the
catalytic domain of PI3KC, oncogenic mutations were
found at Cys901 and Phe909 in k6, at Ser1008 in k9,
at Thr1025 in k10, and at Met1043 and His1047 in
k11 (Figure 1). Activating mutations in the catalytic re-
gion of S. pombe TOR2 were found in or near k3, k5,
k9, and k11 (30). Activating mutations in human TOR
were found in k3, the k4k5 loop and the FIT do-
main (mutant SL2), and k5. The overlap of locations of
activating TOR mutations and locations of oncogenic
mutations in PI3KC supports structural similarity be-
tween TOR and PI3KC.
In the helical domain of PI3KC, oncogenic muta-
tions cluster in residues Glu542, Glu545, Gln546, and
Figure 10. Differences in use of a novel pharmacophore space may be
responsible for TOR speciﬁcity of Ku-0063794. Surface view of TOR
generated by MacPymol (Delano Scientiﬁc), viewed roughly perpen-
dicular to the space, the surface termed “bottom”. TOR domains are
colored as before. A) Docked PP242. B) Docked NVP-BEZ235. C) Docked
Ku-0063794. Note how TOR-speciﬁc Ku-0063794 packs into and nearly
ﬁlls this space.
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see ref 6), this hotspot is near hB1 of PI3KC. In the de-
termined structures for PI3KC (RCSB, PDB 2d0, 3hhm,
3hiz), these residues make contact with the niSH2 frag-
ment of the p85 adapter (4, 39).
In the catalytic region of PI3KC, oncogenic muta-
tions cluster in residues Met1043 and His1047 in k11
and at Gly1049 in the short loop between k11 and
k12 (Figure 1) (38). Mutations at His1047 are more fre-
quent, and their oncogenic effects are potent (40). He-
lix k11 in PI3KC corresponds to helix k12 in PI3KC
(4, 39), the last helix identiﬁed by crystallography at
the C-terminus in PI3KC.
The two activating mutations L2289F and N2294I in
S. pombe TOR2 are in k11. These are a just a few resi-
dues from the His1047 oncogenic hotspot in PI3KC.
His1047 was aligned to Gly2510 in human TOR
(Figure 1). Between Asp2506 and Gly2510, we discov-
eredaKLTmotifthatisconservedinthe100TORsand
found in the FIT domain of ATM (manuscript in prepara-
tion). Tip60 acetylates Lys3016 in the KLT motif of ATM,
and Lys3016 is required for ATM function (41).
Allosteric regulation of ATR requires the FIT domain
of ATR (42, 43). Protein TopBP1 (topoisomerase (DNA)
II binding protein 1) binds PRD (PIKK regulatory domain)
(43) and activates an ATR: ATRIP (ATR interacting pro-
tein) complex. Scanning mutagenesis of the PRD
(equivalent in deﬁnition to FIT domain) identiﬁed muta-
tions (K2589E and HVL2591AAA) that did not inhibit the
basal kinase of ATR but inhibited its activation by
TopBP1 (43). TopBP1 increased kinase activity in vitro,
chieﬂy by decreasing the Km for substrate (42). Where
are the equivalent residues in TOR? ATR Lys2589 aligns
to the short loop between k10 and k11, and residues
His2591, Val2592, and Leu2593 align to k11 (data
not shown). This observation indicates a likelihood that
k11 helix is important in regulation of all PIKKs and
PI3KCs, by multiple mechanisms.
Two hypotheses emerged in building a model of
TOR. The ﬁrst hypothesis is that the helical domain
(FAT plus FRB) of TOR may have a similar general rela-
tion in space to its catalytic domain as the helical do-
main of PI3K has to its catalytic domain, also suggested
in ref 47. Our model cannot predict this portion accu-
rately on the basis of homology because the sequence
similarity is minimal. The second hypothesis is that the
C-terminus of TOR contains a variable insertion (in verte-
brates, including the conserved motif with the S2481
and S2484 phosphorylation sites) that may lie on a sur-
face where a much shorter surface loop lies on the sur-
faceofPI3Kneartheactivesite.Thisinsertionisinaseg-
ment of TOR we name the FIT domain for future
discussion. The FIT domain also contains helices
(k1012) that correspond to conserved helices at the
C-terminus of PI3KCs, to which is appended or incorpo-
rated the FATC domain not present in PI3K.
Recently, the ATP-binding site of TOR was modeled
to a PI3KC structure to rationalize the structure
activity relationship of the novel TOR-selective inhibitor
6-(1H-indol-5-yl)-4-morpholin-4-yl-1-[1-(pyridin-3-
ylmethyl)piperidin-4-yl]-1H-pyrazolo[3,4-d]pyrimidine
(also referred to as 5u) (44). Few details of the model
are provided, but having a model facilitated optimiza-
tion of a lead compound. Template PI3KC contained a
co-crystallized 4-[morpholin-4yl] pyrazolopyrimidine,
and interestingly OH of the morpholine contacts Val882
in the adenine pocket of PI3KC. The molecular core of
4-[morpholine-4yl] pyrazolopyrimidine is more similar to
the core of 4-[morpholine] pyrido[2,3-d]pyrimidine in
small molecule Ku-0063794 than to the pyrazolopyrim-
idine of PP242 (see Supplementary Figure S2) because
of this morpholine moiety. In the putative binding mode
for 5u to the ATP site in TOR, the morpholine makes a
hydrogen bond to the equivalent residue, Val2240, as
we predict for the morpholine moiety in Ku-0063794. Of
more interest, the NH2 of 6-[indole] moiety of 5u is pre-
dicted to contact the COOH of Asp2195 in the RQD mo-
tifofk3,thepreciseelementthatwehypothesizeisim-
portant for kinase activity of PI3KC and PIKKs.
METHODS
Informatics. We obtained sequences for TORs from NCBI,
www.ensembl.org, and the Broad Institute. We compared se-
quences using ClustalW (Gibson) using the server at Pole-
Bioinformatique-Lyonnais. The sequences were inspected and
trimmed to commence at 1800 by BLAST to human
TOR18642549. These were compared to large subsets of
PI3K (classes IIII) and to each other to deduce what was con-
served in PI3KC or TOR.
Structural Alignment. TORs (human, mouse, S. cerevisiae
(TOR1, TOR2) and S. pombe TOR2) were aligned manually, in a
slow process, with sequences for human and zebraﬁsh PI3KC
and human and pig PI3KC. Ability to view sequences with color
codings, including for predicted -helix, -sheet, and structural
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valuable. Cn3D at the NCBI structure depository was helpful in
viewing structural elements and especially the structural posi-
tion (interior versus surface) of loops.
SwissModel Server. Manual alignments of human and yeast
TORs to template were exported in FASTA format to the Swiss-
Model server (25). We used a MacBook Pro (OS10.5.7 and
Xtools) with DeepView v4.0 (Swiss Institute of Bioinformatics),
PyMol (DeLano Scientiﬁc), Chimera (UCSF), and the MGL 1.6.0
package of programs from Scripps Research Institute (35, 36).
Magic Fit in DeepView was used for superposition of chains to
place structure 3ene in the 1e8x reference. For docking, models
for human and yeast TOR with stubs replacing missing loops
were ﬁrst analyzed by Molprobity to add all hydrogens and to
ﬂip Asn, Gln, and His bonds (45). The reduced model with ﬂips
was minimized for energy in Chimera, and Chimera was used to
convert formats. (The PRODRG2 server (46) was used to pro-
duce small molecule structures for AutoDock4 for small mol-
ecules PP242 (5) NVP-BEZ235 (16) and Ku-0063794 (15).
MacPyMOL was used for production of most ﬁgures and for pre-
set analyses of ligand sites (34).
Docking Analyses. MGL tools 1.6.0 with AutoGrid4 and
AutoDock4 (Scripps) were used for docking studies. Most were
with 256 runs with 2,500,000 energy evaluations with the
Lamarckian algorithm for generating populations of 150 ran-
dom positions from the starting position (see text) and other-
wise default settings (35).
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